Regulatory Roundup: FDA Holds Workshop on Orphan Drugs

Article

FDA Holds Workshop on Orphan Drugs

FDA will hold its fourth orphan-drug designation workshop for academics, biotechnology companies, and those unfamiliar with the orhan-drug designation process Feb. 28–Mar. 1, 2011, in Claremont, California, in collaboration with Keck Graduate Institute, according to an agency announcement. The workshop will focus on the process used by FDA to grant orphan-drug designation to drug products intended to treat rare diseases. Three similar workshops were held in 2010.

Recent Videos
Ian Lafferty from Upperton discusses the trends and challenges facing sterile manufacturing and how partnering with CDMOs can help innovators progress to the market.
Miguel Forte from ISCT and Kiji Therapeutics talks about the potential impact of a changing European political landscape.
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Miguel Forte from ISCT and Kiji Therapeutics chats about expectations for 2025 and the future technology agenda for industry.
Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.
Mike Baird from Schlafender Hase gives his predictions for how AI and ML may find use in the industry moving forwards and provides some predictions about M&A and the changing US government administration.
Mike Baird from Schlafender Haser discusses industry trends from 2024 and those expected to have an impact in 2025 from the perspective of a software developer.
Preeya Beczek from Beczek.COM gives her thoughts on the areas to watch with the new US administration and how Europe might be finalizing preparations for previous legislative changes